Table 1 Shows the distribution of salient clinical characteristics of the different treatment groups at study entry
From: Outcomes and costs of Ranibizumab and Aflibercept treatment in a health-service research context
Therapy | # Eyes (patients) | Age (sda) | Male (%) | Visus (sda) | CRT (sda) | DME (%) | CRVO (%) | Mean # IVI before | Treatment duration prior study [months] |
|---|---|---|---|---|---|---|---|---|---|
Only ranibizumab | 182 (144) | 80.0 (8.9) | 63 (34.6) | 64.7 (23.7) | 314.3 (100.3) | 21 (11.5) | 7 (3.8) | 8.7 | 19.5 |
Only aflibercept | 63 (52) | 75.1 (9.4) | 29 (46.0) | 69.4 (18.8) | 361.2 (152.3) | 8 (12.7) | 6 (9.5) | 4.7 | 7.9 |
p-values | < 0.001 | 0.107 | 0.159 | 0.006 | 0.806 | 0.083 | 0.002 | < 0.001 | |
Switching from ranibizumab to aflibercept prior study | 160 (128) | 77.4 (10.2) | 66 (41.3) | 65.8 (25.4) | 304.0 (86.7) | 25 (15.6) | 7 (4.4) | 27.4 | 51.3 |
Switching from ranibizumab to aflibercept during study | 45 (36) | 76.8 (8.7) | 19 (42.2) | 66.7 (23.8) | 323.2 (93.9) | 8 (17.8) | 6 (13.3) | 9.9 | 19.1 |
Miscellaneousb | 38 (34) | 78.9 (8.5) | 10 (26.3) | 57.2 (26.7) | 302.7 (64.3) | 7 (18.4) | 2 (5.3) | 31.8 | 63.5 |